Overview
Anthracycline chemotherapies (e.g. doxorubicin, daunorubicin) is commonly given to treat pediatric cancer, and carries a risk of cardiotoxicity. Over the long term, children who receive these therapies have an increased risk of heart failure and early cardiovascular death. However, current strategies for identifying patients who are at risk prior to the development of significant changes in heart function are limited. This study will focus on imaging markers of cardiac injury and dysfunction with the goal of developing improved diagnostic tests and treatment strategies.
Description
Anthracycline chemotherapies (e.g. doxorubicin, daunorubicin) is commonly given to treat pediatric cancer, and carries a risk of cardiotoxicity. Over the long term, children who receive these therapies have an increased risk of heart failure and early cardiovascular death. However, current strategies for identifying patients who are at risk prior to the development of significant changes in heart function are limited. This study will focus on imaging markers of cardiac injury and dysfunction with the goal of developing improved diagnostic tests and treatment strategies.
Cardiac shape, function, and tissue characteristics will be examined using cardiac MRI data in combination with standard cardiac assessments (by echocardiography, electrocardiograms, and cardiac MRI) to assess the cardiotoxic effects of cancer therapy. Analyses will be performed in a cross-sectional cohort of adolescents and young adults with a history of childhood cancer.
Eligibility
Inclusion Criteria:
- English and Spanish speaking male and female subjects, ages 14-25 years old
- Previously treated for cancer, with diagnosis at least two years prior.
- Patients whose cancer has recurred, persisted, is still detectable, or have developed a secondary cancer will still be eligible.
Exclusion Criteria:
- Patients who have a contraindication to contrast cardiac MRI, including the presence of non-MRI compatible metallic implants and severe renal dysfunction.
- Medical, psychiatric, and/or social disorder that would prevent successful completion of planned study testing or would preclude the subject from undergoing the cardiac MRI without anesthesia.
- Patients with a history of congenital heart disease (more significant than a history of patent foramen ovale or patent ductus arteriosus).
- Patients with orthodontic braces or metallic implants in the thorax or abdomen/lumbar spine, even if MRI-compatible, will be excluded as these may cause artifacts and limit image quality.
- Females who are pregnant.